Quick Answer
Rani Therapeutics Holdings, Inc. reported Long Term Debt of $0.00 for the year ending 2025.
- Rani Therapeutics Holdings, Inc. showed a decrease of -100.0% in Long Term Debt from 2024 to 2025.
- This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.00 | Q3 2021: $0.00 | Q3 2022: $14.09 million | Q1 2023: $29.21 million | Q2 2023: $29.27 million | Q3 2023: $28.10 million | Q1 2024: $20.85 million | Q2 2024: $17.21 million | Q3 2024: $13.54 million | Q1 2025: $5.92 million | Q2 2025: $2.23 million | Q3 2025: $0.00.
- Over the full 6 years of available data (2020 to 2025), Rani Therapeutics Holdings, Inc.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $9.61 million | Fiscal year 2023: $24.48 million | Fiscal year 2022: $29.15 million | Fiscal year 2021: $0.00 | Fiscal year 2020: $2.41 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: